- Home
- XPON vs GNPX Comparison
XPON vs GNPX Comparison
Compare XPON & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPON
- GNPX
- Stock Information
- Founded
- XPON 2016
- GNPX 2009
- Country
- XPON United States
- GNPX United States
- Employees
- XPON N/A
- GNPX N/A
- Industry
- XPON Electronic Components
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- XPON Technology
- GNPX Health Care
- Exchange
- XPON Nasdaq
- GNPX Nasdaq
- Market Cap
- XPON 6.2M
- GNPX 5.5M
- IPO Year
- XPON 2022
- GNPX 2018
- Fundamental
- Price
- XPON $1.24
- GNPX $0.29
- Analyst Decision
- XPON
- GNPX
- Analyst Count
- XPON 0
- GNPX 0
- Target Price
- XPON N/A
- GNPX N/A
- AVG Volume (30 Days)
- XPON 2.3M
- GNPX 24.3M
- Earning Date
- XPON 08-13-2025
- GNPX 11-12-2025
- Dividend Yield
- XPON N/A
- GNPX N/A
- EPS Growth
- XPON N/A
- GNPX N/A
- EPS
- XPON N/A
- GNPX N/A
- Revenue
- XPON $8,414,250.00
- GNPX N/A
- Revenue This Year
- XPON $61.26
- GNPX N/A
- Revenue Next Year
- XPON N/A
- GNPX N/A
- P/E Ratio
- XPON N/A
- GNPX N/A
- Revenue Growth
- XPON 68.33
- GNPX N/A
- 52 Week Low
- XPON $0.60
- GNPX $0.14
- 52 Week High
- XPON $22.81
- GNPX $3.97
- Technical
- Relative Strength Index (RSI)
- XPON 45.47
- GNPX 68.08
- Support Level
- XPON $1.15
- GNPX $0.20
- Resistance Level
- XPON $1.49
- GNPX $0.40
- Average True Range (ATR)
- XPON 0.15
- GNPX 0.04
- MACD
- XPON -0.04
- GNPX 0.02
- Stochastic Oscillator
- XPON 19.85
- GNPX 57.14
About XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.